The impact of human herpesvirus-6 and -7 infection on the outcome of liver transplantation

Liver Transplantation

Volumn 8, Issue 8, 2002, Pages 651-658

  Razonable, Raymund R ^a   Paya, Carlos V ^a,b  

^a Division of Cardiovascular Diseases and Internal Medicine   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CIDOFOVIR; FOSCARNET; GANCICLOVIR;

BONE MARROW SUPPRESSION; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; ENCEPHALITIS; FEVER; HEPATITIS; HERPES VIRUS INFECTION; HOST; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; IMMUNE DEFICIENCY; LATENT VIRUS INFECTION; LIVER TRANSPLANTATION; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; RASH; RECIPIENT; REVIEW; TREATMENT OUTCOME; VIRUS REACTIVATION; VIRUS REPLICATION; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; VIROLOGY; VIRUS INFECTION;

HERPESVIRUS 6, HUMAN; HERPESVIRUS 7, HUMAN; HUMANS; LIVER TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; ROSEOLOVIRUS INFECTIONS; TREATMENT OUTCOME;

EID: 0036023920     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2002.34966     Document Type: Article

References (66)

1. Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders
2. Identification of human herpesvirus-6 as a causal agent for exanthem subitum
3. Primary human herpesvirus 6 infection in young children
4. Human herpesvirus-6 infection in children. A prospective study of complications and reactivation
5. Genetic content of a 20.9 kb segment of human herpesvirus 6B strain Z29 spanning the homologs of human herpesvirus 6A genes U40-57 and containing the origin of DNA replication
6. The DNA sequence of human herpesvirus-6: Structure, coding content, and genome evolution
7. Human herpesvirus 6
8. Human herpesvirus 6 (HHV-6) variant B accounts for the majority of symptomatic primary HHV-6 infections in a population of U.S. infants
9. Selective reactivation of human herpesvirus 6 variant A occurs in critically ill immunocompetent hosts
10. Isolation of a new herpesvirus from human CD4+ T cells
11. Human herpesvirus-6 and -7 in transplantation
12. Prevalence of antibody to human herpesvirus 7 by age
13. Human herpesvirus 7: Another causal agent for roseola (exanthem subitum)
14. Human herpesviruses 6 and 7: Identification of newly recognized viral pathogens and their association with human disease
15. Human herpesvirus 7 is a T-lymphotropic virus and is related to, but significantly different from, human herpesvirus 6 and human cytomegalovirus
16. Impact of cytomegalovirus infection on organ transplant recipients
17. Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopoietic stem cell and solid-organ transplant recipients
18. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation
19. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: A randomized, placebo-controlled trial
20. Comparative quantitation of cytomegalovirus (CMV) DNA in solid organ transplant recipients with CMV infection by using two high-throughput automated systems
21. The economic impact of cytomegalovirus infection after liver transplantation
22. Cytomegalovirus disease is associated with increased cost and hospital length of stay among orthotopic liver transplant recipients
23. Bone marrow suppression by human herpesvirus-6: Comparison of the A and B variants of the virus
24. High levels of human herpesvirus 6 DNA in peripheral blood leucocytes are correlated to platelet engraftment and disease in allogeneic stem cell transplant patients
25. Interstitial pneumonitis associated with human herpesvirus-6 infection after marrow transplantation
26. Human herpesvirus 6 in lung tissue from patients with pneumonitis after bone marrow transplantation
27. Human herpes virus (HHV) 6 and HHV7 cause cytomegalovirus (CMV)-negative CMV syndromes among transplant patients (TXP)
28. Variant B human herpesvirus-6 associated febrile dermatosis with thrombocytopenia and encephalopathy in a liver transplant recipient
29. Fever in liver transplant recipients: Changing spectrum of etiologic agents
30. Human herpesvirus-6 infection after liver transplantation
31. Human herpesvirus-6 is associated with cytomegalovirus reactivation in liver transplant recipients
32. Human beta-herpesvirus interactions in solid organ transplant recipients
33. Human herpesvirus-6 in liver transplant recipients: Role in pathogenesis of fungal infections, neurologic complications, and outcome
34. Human herpesvirus 6 seronegativity before transplantation predicts the occurrence of fungal infection in liver transplant recipients
35. Brief report: Primary human herpesvirus 6 infection in a patient after liver transplantation from a seropositive donor
36. Human herpesvirus type 7 in blood donors: Detection by the polymerase chain reaction
37. Human herpesviruses 6 and 7 in solid organ transplant recipients
38. Clinical impact of human herpesvirus 6 infection after liver transplantation
39. Human herpesvirus-6 infection in liver transplant recipients: Documentation of pathogenicity
40. Neuroinvasion and persistence of human herpesvirus 6 in children
41. Encephalitis caused by human herpesvirus-6 in transplant recipients: Relevance of a novel neurotropic virus
42. Human herpesvirus 6 DNA in cerebrospinal fluid specimens from allogeneic bone marrow transplant patients: Does it have clinical significance?
43. Human herpesvirus 6 reactivation is associated with cytomegalovirus infection and syndromes in kidney transplant recipients at risk for primary cytomegalovirus infection
44. Prospective study of human β-herpesviruses after renal transplantation: Association of human herpesvirus 7 and cytomegalovirus co-infection with cytomegalovirus disease and increased rejection
45. "Cytomegalovirus disease" in renal allograft recipients: Is human herpesvirus 7 a co-factor for disease progression?
46. Association of human herpesvirus 7 with cytomegalovirus disease in renal transplant recipients
47. Productive infection of CD4+ and CD8+ mature human T cell populations and clones by human herpesvirus 6. Transcriptional down-regulation of CD3
48. Apoptosis of CD4+ T lymphocytes in human herpesvirus-6 infection
49. Human herpesvirus 6 induces interleukin-1 beta and tumor necrosis factor alpha, but not interleukin-6, in peripheral blood mononuclear cell cultures
50. Immunosuppressive effect of human herpesvirus 6 on T-cell functions: Suppression of interleukin-2 synthesis and cell proliferation
51. CD46 is a cellular receptor for human herpesvirus 6
52. Infection of natural killer cells by human herpesvirus 6
53. In vitro cellular tropism of human B-lymphotropic virus (human herpesvirus-6)
54. CD4 is a critical component of the receptor for human herpesvirus 7: Interference with human immunodeficiency virus
55. Human herpesvirus-6 infection may predispose cells to superinfection by other viruses
56. Association of human herpesvirus 6 reactivation with severe cytomegalovirus-associated disease in orthotopic liver transplant recipients
57. Longitudinal study of human herpesvirus 6 infection in organ transplant recipients
58. Human herpesviruses 6 and 7 as potential pathogens after liver transplant: Prospective comparison with the effect of cytomegalovirus
59. Cytomegalovirus viremia: Risk factor for allograft cirrhosis after liver transplantation for hepatitis C
60. Human herpesvirus-6 antigenemia after liver transplantation
61. In vitro sensitivity of human herpesvirus-6 to antiviral drugs
62. Susceptibility of human herpesvirus 6 to acyclovir and ganciclovir
63. Susceptibility of human herpesvirus 6 to acyclovir and ganciclovir
64. Susceptibility of human herpesvirus 6 to antivirals in vitro
65. The prevalence of human herpesvirus-7 in renal transplant recipients is unaffected by oral or intravenous ganciclovir
66. Comparison of antiviral compounds against human herpesvirus 6 and 7